methylphenidate - Page 1 | CARLAT PUBLISHING

Clinical Update

ADHD Update 2025: New Treatments and Current Approaches for Co-Occurring Conditions

July 1, 2025

Anne Buchanan, DO. Child and adolescent psychiatrist; Medical Director, Caring Transitions Program, NYC Health + Hospitals, New York, NY.

Dr. Buchanan has no financial relationships with companies related to this material.

Where is ADHD care today? This comprehensive update covers the latest stimulant formulations, nonstimulant innovations, and digital therapeutics. We also provide evidence-based approaches for managing ADHD with common comorbidities including anxiety, depression, autism, bipolar disorder, and psychosis.

Research Update

Long-Term Cardiovascular Risks of ADHD Medications: A Closer Look

April 1, 2025

Joshua Feder, MD

Josh Feder, MD. Dr. Feder has no financial relationships with companies related to this material.

We know that stimulant medications for ADHD can reduce chronic health conditions and extend healthy years for patients. But are there cardiovascular risks from these or non-stimulant medications used for ADHD? In this research update, we review a study that helps clarify the risks of long term use in youth and adults.

Expert Q&A

Antipsychotics and Weight Gain in Younger Patients

April 1, 2025

Julie Ann Dopheide, PharmD, BCPP, FASHP

Julie Ann Dopheide, PharmD, BCPP, FASHP, Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and Keck School of Medicine, University of Southern California, Los Angeles, CA.
Dr. Dopheide has no financial relationships with companies related to this material.

Clinical Update

How to Select a Stimulant for Adult ADHD

March 1, 2025

Greg Malzberg, MD

Gregory Malzberg, MD. Attending Psychiatrist & Assistant Clinical Professor, Mount Sinai West, New York, NY. Creator, PsychoFarm.

Dr. Malzberg has no financial relationships with companies related to this material.

We have 30 stimulant formulations, but do all deserve prizes? We find a few with niche advantages, and three that rise to the top.

Research Update

How Safe Is Methylphenidate?

October 1, 2024

Earth Hasassri, MD

Earth Hasassri, MD. Dr. Hasassri has no financial relationships with companies related to this material.

Most of us use methylphenidate (MPH) routinely in patients across a wide range of ages and even diagnoses. But what are the long-term side effects of MPH? This research update gives you a current understanding of the potential risks with helpful guidance on how to proceed with care.

Research Update

Stimulants in Preschool-Age Children

October 1, 2024

Earth Hasassri, MD

Earth Hasassri, MD. Dr. Hasassri has no financial relationships with companies related to this material.

We are understandably hesitant to treat young children with medication for ADHD. Does it work? Will there be worse or different side effects? This research update will help you weigh the risks and benefits of pursuing stimulant treatment for ADHD in our smallest patients.

Clinical Update

Boost or Bust: Navigating the Risks of Prescription Stimulants

October 1, 2024

David Stiffler, MD and Noah Capurso, MD

David Stiffler, MD. Clinical Associate Professor of Psychiatry and Medical Director of the Steven A. Cohen Military Family Center at NYU Grossman School of Medicine, New York, NY.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Stiffler and Capurso have no financial relationships with companies related to this material.

Prescription stimulants, while effective for treating ADHD, are widely taken without a prescription, particularly by young adults for cognitive enhancement, weight loss, and recreational purposes. This misuse poses serious risks, from developing stimulant use disorder to experiencing severe cardiovascular and psychiatric effects. In this article, you'll learn about the prevalence and patterns of stimulant misuse, its associated dangers, and tips on how to manage it in clinical practice.

Clinical Update

The Antipsychotic-Stimulant Combo

September 1, 2023

Avneet Soin, MD., Chris Aiken, MD, and Deepti Anbarasan, MD.

Avneet Soin, MD. Psychiatry resident, NYU Grossman School of Medicine. Deepti Anbarasan, MD. Associate Professor, Psychiatry & Neurology, New York University, New York.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report; Assistant Professor, NYU Langone Department of Psychiatry; practicing psychiatrist, Winston-Salem, NC.

Deepti Anbarasan, MD. Associate Professor, Psychiatry & Neurology, New York University, New York

Dr. Soin, Dr. Anbarasan, and Dr. Aiken have no financial relationships with companies related to this material.

As antipsychotic indications have spread, more patients are taking them in combination with their opposite: a stimulant. We look at the risks, search for scenarios where it might make sense, and come up with an action plan for this paradoxical pairing.

Clinical Update

Stimulant Dosing Limits

August 7, 2023

Chris Aiken, MD and Kelvin Quiñones-Laracuente, MD, PhD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Kelvin Quiñones-Laracuente, MD, PhD. Psychiatry resident, NYU Langone Medical Center.

Drs. Aiken and Quiñones-Laracuente have no financial relationships with companies related to this material.

Dosing is not a collaborative venture when it comes to controlled substances, and here we look for the safe upper limits of stimulant dosing.

Research Update

Does Treatment of ADHD Help Caregiver Stress?

April 1, 2023

Muruga Loganathan, MD

Muruga Loganathan, MD. Dr. Loganathan has no financial relationships with companies related to this material.

Parents suffer significant stress, doing their best to support and care for their ADHD kids. Does that stress dissipate at all when the ADHD is alleviated? This controlled trial looked at stress levels of parents whose kids were taking delayed release/extended release methylphenidate versus those taking placebo.